Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists.

Okamoto A, Yokokawa H, Nagamine T, Fukuda H, Hisaoka T, Naito T

Journal of diabetes and metabolic disorders25 Sept 2021Cited by 25 (Europe PMC)

PMID34900848PMCIDPMC8630305DOI10.1007/s40200-021-00899-9PepBankPUB-34900848

Summary

PurposeEvidence of the efficacy and safety of semaglutide among patients with type 2 diabetes who were initiated on or were switched to semaglutide from other GLP-1 RAs remains limited. The objective of this study was to investigate the short-term effects of switching to semaglutide from other GLP-1 RAs.MethodsThis retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity. HbA1c, body weight, serum creatinine, serum uric acid, parameters of lipid metabolism, and parameters of liver function were measured before and 6 months after administration of semaglutide.ResultsA total of 50 patients were registered in the study. After switching to semaglutide (n = 43), HbA1c and body weight significantly decreased (p p < 0.01), respectively. The same findings were observed in semaglutide-naïve patients (p = 0.04, p < 0.02) (n = 7). Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well (p = 0.04, p = 0.04, p = 0.02, p = 0.04), whereas serum creatinine did not change significantly (p = 0.51).ConclusionsSemaglutide showed excellent efficacy, even in patients switched from other GLP-1 RAs. Semaglutide appears to be a promising agent for blood glucose and body weight control in obese type 2 diabetes mellitus patients and could be more potent in treating type 2 diabetes than existing GLP-1 RAs.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, serum uric acid decreased significantly 6 months after semaglutide.
In plain wordsIn people with type 2 diabetes, uric acid in the blood went down 6 months after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseSerum uric acid
Study
n = 50
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well (p = 0.04, p = 0.04, p = 0.02, p = 0.04), whereas serum creatinine did not change significantly (p = 0.51).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity.
Show in the study text Report a problemFND-3490084805
02HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, total cholesterol decreased significantly 6 months after semaglutide.
In plain wordsIn people with type 2 diabetes, total cholesterol went down 6 months after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseTotal cholesterol
Study
n = 50
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well (p = 0.04, p = 0.04, p = 0.02, p = 0.04), whereas serum creatinine did not change significantly (p = 0.51).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity.
Show in the study text Report a problemFND-3490084806
03HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, triglycerides decreased significantly 6 months after semaglutide.
In plain wordsIn people with type 2 diabetes, triglycerides went down 6 months after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseTriglycerides
Study
n = 50
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well (p = 0.04, p = 0.04, p = 0.02, p = 0.04), whereas serum creatinine did not change significantly (p = 0.51).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity.
Show in the study text Report a problemFND-3490084807
04HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, the urinary albumin-creatinine ratio decreased significantly 6 months after semaglutide.
In plain wordsIn people with type 2 diabetes, the urine albumin-to-creatinine ratio went down 6 months after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseUrinary albumin-creatinine ratio
Study
n = 50
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well (p = 0.04, p = 0.04, p = 0.02, p = 0.04), whereas serum creatinine did not change significantly (p = 0.51).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity.
Show in the study text Report a problemFND-3490084808
05HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, serum creatinine did not change significantly 6 months after semaglutide.
In plain wordsIn people with type 2 diabetes, blood creatinine did not change clearly 6 months after starting semaglutide.
Peptide
Semaglutide
Outcome
No significant changeSerum creatinine
Study
n = 50
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well (p = 0.04, p = 0.04, p = 0.02, p = 0.04), whereas serum creatinine did not change significantly (p = 0.51).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity.
Show in the study text Report a problemFND-3490084809
06HumanObservational studyEfficacy outcome
In patients with type 2 diabetes switched to semaglutide from other GLP-1 receptor agonists, HbA1c decreased significantly after 6 months.
In plain wordsIn people with type 2 diabetes who switched to semaglutide, HbA1c went down after 6 months.
Peptide
Semaglutide
Outcome
DecreaseHbA1c after switching to semaglutide
Study
n = 43
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After switching to semaglutide (n = 43), HbA1c and body weight significantly decreased (p p < 0.01), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity.
Show in the study text Report a problemFND-3490084801
07HumanObservational studyEfficacy outcome
In patients with type 2 diabetes switched to semaglutide from other GLP-1 receptor agonists, body weight decreased significantly after 6 months.
In plain wordsIn people with type 2 diabetes who switched to semaglutide, body weight went down after 6 months.
Peptide
Semaglutide
Outcome
DecreaseBody weight after switching to semaglutide
Study
n = 43
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After switching to semaglutide (n = 43), HbA1c and body weight significantly decreased (p p < 0.01), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity.
Show in the study text Report a problemFND-3490084802
08HumanObservational studyEfficacy outcome
In semaglutide-naive patients with type 2 diabetes, HbA1c decreased significantly after 6 months.
In plain wordsIn people with type 2 diabetes new to semaglutide, HbA1c went down after 6 months.
Peptide
Semaglutide
Outcome
DecreaseHbA1c in semaglutide-naive patients
Study
n = 7
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The same findings were observed in semaglutide-naïve patients (p = 0.04, p < 0.02) (n = 7).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity.
Show in the study text Report a problemFND-3490084803
09HumanObservational studyEfficacy outcome
In semaglutide-naive patients with type 2 diabetes, body weight decreased significantly after 6 months.
In plain wordsIn people with type 2 diabetes new to semaglutide, body weight went down after 6 months.
Peptide
Semaglutide
Outcome
DecreaseBody weight in semaglutide-naive patients
Study
n = 7
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The same findings were observed in semaglutide-naïve patients (p = 0.04, p < 0.02) (n = 7).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity.
Show in the study text Report a problemFND-3490084804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.